Nanjing Vcare Assisted Lizhu Pharmaceutical to Obtain the Production Approval Letter of Pantoprazole Sodium for Injection

2022-12-27

Recently, the production approval letter of pantoprazole sodium for injection cooperated by Nanjing Vcare and Lizhu Pharmaceutical Factory was successfully obtained. In the cooperation of this project, Nanjing Vcare gave full play to the advantages of whole production chain and whole life cycle services, completed the registration acceptance after 14 months, and obtained the production approval letter after 24 months. This project is another important cooperation progress following the consistency evaluation of the quality and efficacy of generic drugs of Omeprazole Sodium for Injection by Vcare Assisted Lizhu Pharmaceutical in June 2021.

Pantoprazole Sodium for Injection is a Class B national medical insurance variety, which is used for digestive system and is mainly used for acute upper gastrointestinal bleeding such as duodenal ulcer, gastric ulcer, acute gastric mucosal lesion and compound gastric ulcer. The acquisition of the production approval letter for pantoprazole sodium for injection not only strongly assists Lizhu Pharmaceutical in contributing to the healthy development of the pharmaceutical industry "Lizhu Force", but also highlights the development potential of Nanjing Vcare as a new force in the pharmaceutical CRO/CDMO industry.

Prev

Nanjing Vcare Helps Nanjing Chiatai Tianqing's Anti-tumor New Drug CXA03 to Obtain the Clinical Approval

Next

Nanjing Vcare Ranked 10th on the "Top 20 Chinese Pharmaceutical CRO Enterprises in 2022"